Frontotemporal dementia: Research & Drug Discovery Data

Drug discovery

drugs

With orphan designations

Overview

Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by progressive atrophy of the frontal and temporal lobes, leading to behavioral changes, language deficits, and/or motor dysfunction. It is distinguished from Alzheimer’s disease by earlier onset (typically 45–65 years), relative preservation of memory in early stages, and prominent personality or language alterations [1][2][6]. Subtypes include behavioral variant FTD, primary progressive aphasia, and motor disorders like corticobasal syndrome [1][11]. Neuropathology involves tau or TDP-43 protein accumulation [1][14].

Population

Affects ~15/100,000 people aged 45–64, with comparable prevalence to early-onset Alzheimer’s in this group [4][12].
Lifetime risk: 1 in 742; median survival ranges from 2.9 years (progressive supranuclear palsy) to 9.1 years (semantic variant FTD) [4][14].
Equal sex distribution, though behavioral variant FTD shows male predominance [12][17].

Burden

Leads to 6–11 years of dependency post-diagnosis, often requiring full-time care [7][17].
Economic strain: 40% of patients have familial forms, with 50% risk to offspring [17]; misdiagnosis delays average 3.6 years [7][9].
Caregiver stress peaks due to behavioral symptoms (apathy, impulsivity) and young onset disrupting work/family roles [6][16].

Therapies

Pharmacological: Off-label SSRIs (e.g., citalopram) for disinhibition/compulsions [3][8], low-dose antipsychotics (e.g., quetiapine) for agitation [8][18]. No disease-modifying therapies exist [2][10].
Non-pharmacological: Behavioral interventions, speech/occupational therapy, and caregiver education [3][18].
Research focus: Targeting tau/TDP-43 pathology and genetic variants (e.g., C9orf72) [5][14].

Categories: rare genetic diseases, rare neurological diseases

Research Papers

1,937 drug discovery papers related to Frontotemporal dementia, with 5 first-in-class and 12 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

2026-07-10 | Small molecules targeting ARF1 interaction with C9orf72:SMCR8:WDR41 complexes suppress its overactivation implicated in ALS/FTD.

The hexanucleotide repeat expansion in C9orf72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD). The C9orf72 protein forms a complex with SMCR8 and WDR41 (CSW), which functions as a GTPase-activating protein (GAP) regulating ARF1 and RAB small GTPases. While these findings implicated ARF1-GAP dysregulation in ALS/FTD and supported ARF1 suppression as potential intervention, small molecules that modulate ARF1-CSW interactions are lacking. In this study, we demonstrated upregulation of tyrosine-phosphorylated (Tyr-782) ASAP1 (also known as AMAP1, DDEF1, or Centaurin β4), an ARF-GAP, in human motor cortex of both sporadic ALS and ALS with C9orf72 mutations. Ectopic C9orf72 expression partially mimicked the effects of a known ARF1 inhibitor brefeldin A to disperse Golgi apparatus. Computer-aided rational drug design with high-throughput in-silico screening identified MCULE-5095997944 (Named as SCC944) as a ARF1-CSW modulator. SCC944 binds directly to ARF1 and reduced GTP-bound ARF1 levels upon ARF1 activation. SCC944 demonstrated brefeldin A-like ARF1-dependent alteration of organelle organization including Golgi, microtubules, and mitochondria, but also a protein trafficking pattern that is distinct from brefeldin A mechanism. These studies identified the first small molecule targeting ARF1-CSW interaction and further support ARF1 modulation as a potential therapeutic approach for ALS/FTD.

Open article ↗

2026-07-10 | The NORAD -pumilio regulatory axis links lncRNA dysregulation to tau propagation-associated phenotypes.

Long non-coding RNAs (lncRNAs) are increasingly implicated in neurodegenerative disease, yet their roles in tauopathy remain poorly understood. Here, we defined the lncRNA landscape across iPSC-derived neurons, astrocytes, and microglia harboring the frontotemporal dementia-associated MAPT IVS10+16 mutation and investigated how lncRNA dysregulation interfaces with tau pathology. Transcriptomic analyses revealed extensive cell-type specific lncRNA expression changes, with neurons exhibiting the greatest degree of mutation-associated remodeling. Comparative analyses with MAPT IVS10+16 patient brain tissue identified NORAD and MIR22HG as lncRNAs significantly dysregulated across all three cell types and human brains. NORAD was also altered in Alzheimer's disease and Parkinson's disease brains, suggesting a broader role in neurodegenerative disease. Mechanistically, NORAD -associated protein networks converged on pathways related to RNA regulation, cytoskeletal organization, proteostasis, and tau interaction networks. Given the established role of NORAD in regulating PUM1 and PUM2 RNA-binding (pumilio) proteins, we examined the NORAD -pumilio axis and identified enrichment of pumilio-associated pathways linked to autophagy, endocytosis, proteostasis, and cytoskeletal regulation. NORAD depletion reduced tau seeding and uptake, whereas functional depletion of PUM1 or PUM2 increased both processes, supporting an antagonistic relationship between NORAD and pumilio signaling in modulation of tau aggregation. Together, these findings identify widespread lncRNA dysregulation across neural cell types in the setting of a MAPT mutation and nominate the NORAD -pumilio axis as a regulatory pathway linking RNA homeostasis and tau propagation biology.

Open article ↗

2026-07-10 | Dysregulated neuronal mRNA transport and translation in FTD/ALS.

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are fatal, co-occurring neurodegenerative disorders. Dysregulation of mRNA metabolism, transport, and local translation is a significant mechanism contributing to FTD/ALS. Here, we review the processes of neuronal RNA transport and translation, their disruption in FTD/ALS, and mechanistic interplay between the two. Finally, we discuss current progress targeting transport and translation defects and identify potential future directions for therapeutic development.

Open article ↗

2026-07-10 | Small molecules targeting ARF1 interaction with C9orf72:SMCR8:WDR41 complexes suppress its overactivation implicated in ALS/FTD.

Open article ↗

2026-07-10 | The NORAD -pumilio regulatory axis links lncRNA dysregulation to tau propagation-associated phenotypes.

Open article ↗

2026-07-10 | Dysregulated neuronal mRNA transport and translation in FTD/ALS.

Open article ↗

Access all drug discovery articles and probability of success in trials forecasts:

Request access

Drug Discovery Landscape

20 orphan drug designations for Frontotemporal dementia.

Drug	Therapy type	Regulator	Orphan designation	Approval	Sponsor
neflamapimod	small molecules	FDA	2024-11-25	—	EIP Pharma, LLC
Sodium selenate	small molecules	EMA	2024-10-11	—	Monash University
Rifampin	small molecules	FDA	2023-03-07	—	Medilabo RFP, Inc.
Autologous human bone marrow-derived haematopoietic and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytes	cell therapies	EMA	2022-08-10	—	Neuroplast B.V.
Adeno-associated virus vector serotype 9 encoding the human GRN gene	gene therapies	EMA	2021-12-10	—	Scendea (NL) B.V.
Recombinant AAV9 vector encoding the human progranulin (PGRN) gene	gene therapies	FDA	2021-11-24	—	AviadoBio Ltd.
Latozinemab	antibodies	EMA	2021-10-18	—	Glaxosmithkline Trading Services Limited
Adeno-associated virus vector serotype 1 containing the human GRN gene	gene therapies	EMA	2021-07-19	—	Pharma Gateway AB
Non-replicating recombinant adeno-associated virus serotype 1 vector delivering human GRN gene encoding the protein progranulin	gene therapies	FDA	2021-01-07	—	Passage Bio, Inc.
Adeno-associated viral vector serotype 9 expressing codon-optimized human GRN gene	gene therapies	EMA	2020-11-13	—	PPD Bulgaria EOOD
Fasudil	small molecules	FDA	2020-09-09	—	Woolsey Pharmaceuticals, Inc.
Non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene	gene therapies	FDA	2019-12-05	—	Prevail Therapeutics
recombinant human anti-human sortilin (SORT1) IgG1 G1m17,1 [or G1m (z,a)] kappa monoclonal antibody	antibodies	FDA	2019-07-22	—	Alector, Inc.
hydromethylthionine mesylate	small molecules	FDA	2018-11-20	—	Tau Rx Therapeutics Management Ltd.
recombinant human anti-human Sortilin (SORT1) monoclonal IgG1 G1m17,1 [or G1m (z,a)] kappa monoclonal antibody	antibodies	FDA	2018-06-18	—	Alector
Isoindolin-1,3-Di Thione	small molecules	FDA	2016-11-21	—	P2D, Inc.
tolfenamic acid	small molecules	FDA	2016-07-13	—	Nasser H. Zawia
1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one	small molecules	FDA	2016-04-06	—	Anavex Life Sciences Corp.
peptide fraction derived from porcine brain protein	peptides	FDA	2016-04-05	—	EVER Neuro Pharma GmbH
Methylthioninium	small molecules	EMA	2010-11-26	—	Pharma Gateway AB

Frontotemporal dementia

Frontotemporal dementia

Frontotemporal dementia

Overview

Population

Burden

Therapies

Categories: rare genetic diseases, rare neurological diseases

Research Papers

2026-07-10 | Small molecules targeting ARF1 interaction with C9orf72:SMCR8:WDR41 complexes suppress its overactivation implicated in ALS/FTD.

2026-07-10 | The NORAD -pumilio regulatory axis links lncRNA dysregulation to tau propagation-associated phenotypes.

2026-07-10 | Dysregulated neuronal mRNA transport and translation in FTD/ALS.

2026-07-10 | Small molecules targeting ARF1 interaction with C9orf72:SMCR8:WDR41 complexes suppress its overactivation implicated in ALS/FTD.

2026-07-10 | The NORAD -pumilio regulatory axis links lncRNA dysregulation to tau propagation-associated phenotypes.

2026-07-10 | Dysregulated neuronal mRNA transport and translation in FTD/ALS.

Drug Discovery Landscape

Updated: Jul 29, 2026